How to Inject Retatrutide: Escalation Schedule, Vial Preparation and Technique

Retatrutide is injected subcutaneously once a week, most commonly into the abdomen, with a 2 → 4 → 6 → 9 → 12 mg dose-escalation schedule at 4-week intervals matching Eli Lilly's TRIUMPH Phase 3 trial protocols. This guide covers reconstitution, dose calculation, injection technique, site rotation, and the trial-validated frequency — anchored to the actual published protocols rather than community guesswork.

Retatrutide (LY3437943) is an investigational drug. As of April 2026 it is not FDA-approved and is in Phase 3 development across the eight-trial TRIUMPH program; the first successful Phase 3 readout (TRIUMPH-4, December 2025) reported 28.7% body-weight reduction at 12 mg over 68 weeks. People who buy retatrutide from research-peptide vendors anyway — which is who this article is written for — benefit from injection guidance that mirrors what trial participants actually do, rather than ad-hoc protocols invented online.

For the underlying science and full receptor pharmacology, see the retatrutide compound profile. For the dose math on your specific vial size and BAC water configuration, use Peptigrity's retatrutide dose calculator — it handles the units-per-injection conversion automatically. Peptigrity is an independent peptide review platform — we do not sell peptides, take no affiliate commissions from any vendor, and have no commercial relationship with Eli Lilly. That independence is what allows this article to describe the dose-escalation schedule, the dysesthesia side effect, and the practical injection technique honestly, without a vendor incentive shaping the framing.

How often do you inject retatrutide?

Retatrutide is injected once a week. The compound has an approximately 6-day half-life, achieved by conjugating the peptide to a fatty diacid moiety that binds albumin and slows clearance. Once-weekly subcutaneous administration is the schedule used across the entire Phase 3 TRIUMPH program, including TRIUMPH-4, which reported 28.7% body-weight reduction at 12 mg weekly over 68 weeks (December 2025). Twice-weekly or daily dosing is not supported by any trial data; the half-life is engineered specifically for weekly use, and splitting the weekly dose into smaller daily fractions does not produce additional benefit.

The practical implication: choose one day a week and inject on that day every week. Most users pick a day they will reliably remember — Sunday evening is common because it bookends the week, but any day works. Consistency matters more than the specific day; the molecule's pharmacokinetics produce stable plasma exposure regardless of which day you pick. If you need to shift the day once (Sunday to Monday, for example), shift it once and continue on the new day going forward.

Why retatrutide is weekly, not daily

The 6-day half-life is the answer. Retatrutide's molecular structure includes a C20 fatty diacid side chain that binds reversibly to plasma albumin, dramatically slowing renal clearance compared to the parent peptide. This is the same engineering principle used for semaglutide (which uses a similar fatty diacid linker) and tirzepatide. After a single subcutaneous injection, peak plasma concentrations are reached within 24–48 hours, and concentrations decline slowly over the following week — by the time the next dose is due, ~50% of the previous week's dose remains in circulation. Daily dosing would simply pile on top of an already-high plasma level without producing additional weight-loss benefit, while multiplying injection burden and likely worsening gastrointestinal side effects.

What if I miss a weekly dose?

Phase 3 trial protocols handle missed doses with a simple rule: if you remember within 3–4 days of the missed injection, inject as soon as possible and resume your regular weekly schedule the following week (counted from the original day). If you remember more than 4 days late — which means the next dose is approaching — skip the missed dose entirely and inject the next scheduled dose on its normal day. Do not double-dose to compensate for a missed injection. Doubling the weekly dose dramatically increases the probability of severe nausea and vomiting and is not how the trials handled this scenario.

How much retatrutide do you inject? (The trial-validated escalation schedule)

The TRIUMPH Phase 3 program escalates retatrutide from 2 mg → 4 mg → 6 mg → 9 mg → 12 mg in 4-week intervals, allowing 4 weeks at each step before increasing. Phase 2 data (NEJM 2023) showed 24.2% weight loss at 12 mg over 48 weeks; Phase 3 TRIUMPH-4 confirmed 28.7% at 12 mg over 68 weeks. The escalation is not arbitrary — it exists specifically to titrate gastrointestinal side effects, which are dose-dependent and worst during dose increases. Maintenance doses in the trials are 4 mg, 9 mg, or 12 mg depending on tolerance and response; not all users escalate to 12 mg, and the data suggests many shouldn't.

Schedule extrapolated from TRIUMPH-4 trial protocol (NCT05931367); not all users need or tolerate 12 mg — many maintain effectiveness at 4 mg or 9 mg.

When to stay at a lower dose vs continue escalating

The trial design explicitly allows users to maintain at 4 mg or 9 mg if weight loss is satisfactory or side effects intolerable. The 9 mg arm in TRIUMPH-4 lost 26.4% of body weight versus 28.7% at 12 mg — a 2.3 percentage-point efficacy difference, in exchange for a meaningful difference in dysesthesia incidence (8.8% at 9 mg vs 20.9% at 12 mg) and discontinuation rates (8.8% vs 12.1%). Whether 12 mg is worth those tradeoffs depends entirely on individual response. Many users find 4 mg sufficient — the Phase 2 NEJM data showed 17.1% weight loss at 4 mg over 48 weeks, which exceeds what semaglutide produces at its maximum 2.4 mg dose. The honest framing: escalate only as far as you need to. If you're losing weight at 4 mg and tolerating it well, holding there is a defensible choice supported by the maintenance-arm data.

Can I skip steps or escalate faster?

The 4-week interval is what the trials used to manage gastrointestinal side effects, and the Phase 2 NEJM data made the rationale concrete: a comparison of starting doses showed that participants who started at 4 mg directly produced higher GI side-effect rates than those who started at 2 mg and titrated up. Skipping the 2 mg starting dose, or compressing the 4-week intervals to 2 weeks, increases nausea, vomiting, and discontinuation rates. Stick to the 4-week step intervals unless you're at a stable dose with essentially no side effects — and even then, the marginal benefit of escalating faster doesn't justify the GI cost. The trial schedule is conservative for a reason.

For dose calculations specific to your vial size and BAC water configuration, the retatrutide calculator linked in the intro outputs the exact insulin-syringe units for any combination of vial size and reconstitution volume.

How do you reconstitute retatrutide? (The vial-to-syringe math)

Retatrutide arrives as a lyophilized (freeze-dried) powder in a sealed vial, typically 5 mg, 10 mg, or 20 mg, and must be reconstituted with bacteriostatic water (BAC water — sterile water containing 0.9% benzyl alcohol). Standard practice: add 1–3 mL of BAC water depending on vial size; the choice of BAC water volume sets the final concentration, which then determines how many insulin syringe units equal each weekly dose. The math is straightforward once the variables are fixed — and Peptigrity's retatrutide calculator handles it directly for any vial size.

Verify your specific configuration with Peptigrity's retatrutide calculator — it handles non-standard vial sizes and intermediate doses (6 mg) automatically.

A quick worked example. A 10 mg vial reconstituted with 2 mL of BAC water yields a 5 mg/mL solution. Drawing 18 units on a U-100 insulin syringe equals 0.18 mL, which contains 0.18 × 5 = 0.9 mg of retatrutide — close enough to 1 mg for the purposes of this illustration. For the actual 9 mg weekly dose, draw 36 units (0.36 mL × 5 mg/mL = 1.8 mg... wait, that math doesn't work — let me redo it). For 9 mg at 5 mg/mL, the volume needed is 9 ÷ 5 = 1.8 mL, which is 180 units. That doesn't fit on a single U-100 insulin syringe and would be impractical. Which is exactly why the 10 mg / 2 mL configuration is wrong for higher doses, and why the calculator matters: at the 9 mg and 12 mg dose levels, you need either a higher-concentration reconstitution (10 mg vial in 1 mL = 10 mg/mL, which gives 9 units for 9 mg and 12 units for 12 mg — easy on a single syringe) or a 20 mg vial. The configuration that works for 2 mg titration may not work for 12 mg maintenance, and many users end up adjusting their reconstitution strategy as they escalate.

Step-by-step reconstitution

1. Equilibrate the lyophilized vial to room temperature for ~20 minutes after removing it from the refrigerator. This prevents condensation inside the vial.

2. Disinfect both vial stoppers — the retatrutide vial and the BAC water vial — with separate alcohol pads.

3. Draw the chosen volume of BAC water into a sterile syringe.

4. Inject the BAC water slowly down the side of the retatrutide vial — let it run down the inner glass surface rather than directing the stream onto the lyophilized powder cake. Direct stream impact can fragment the peptide.

5. Wait and swirl gently. Allow the powder to dissolve passively over 1–2 minutes; gently swirl the vial. Do not shake. Vigorous shaking can fragment peptide bonds and is the most common reconstitution error.

6. Inspect. Once fully dissolved, the solution should be clear with no visible particles or cloudiness. If cloudy or granular, do not use; the vial may be degraded or contaminated.

7. Refrigerate at 2–8°C and use within 28 days post-reconstitution. After 28 days, the BAC water's preservative system loses effectiveness regardless of refrigeration.

For the broader walkthrough on peptide reconstitution applicable to any compound, see Peptigrity's step-by-step peptide reconstitution guide, the reconstitution calculator for general reconstitution math, and the BAC water calculator if you're working out volumes from scratch.

BAC water vs sterile water — does it matter?

Yes, materially. Bacteriostatic water contains 0.9% benzyl alcohol as a preservative, allowing the reconstituted peptide to be drawn from the vial repeatedly over ~28 days at refrigerated temperature. Sterile water (without preservative) lacks this preservation system and is generally suitable only for single-use within hours of reconstitution. For weekly retatrutide use across multiple weeks from one vial, BAC water is the correct choice — using sterile water for a multi-dose vial introduces real microbial contamination risk over the 4–10 weeks you'll typically draw from that vial. Most peptide vendors ship BAC water alongside the lyophilized vials specifically because it's the appropriate diluent for multi-dose use; if your shipment is missing BAC water, source it from a pharmacy or research-supply vendor before reconstitution.

How and where do you inject retatrutide? (Sites, technique, depth)

Retatrutide is injected subcutaneously — into the fat layer just below the skin — using a short, thin insulin needle (typically 27–31 gauge, 5/16" or 1/2" length). The three approved injection sites are the abdomen (most common), the thigh (front-outer aspect), and the back of the upper arm. The injection is shallow, not into muscle. The needle goes in at a 90-degree angle for the standard 5/16" needle on most adults; a 45-degree angle is used for very lean individuals. For broader context on subcutaneous versus intramuscular injection technique, see Peptigrity's subcutaneous vs intramuscular injection explainer.

How to inject retatrutide in the stomach (step-by-step)

The abdomen is the default site for retatrutide self-injection because it has the deepest, most consistent subcutaneous tissue layer and is the easiest site to reach without contortion. Most TRIUMPH trial participants used the abdomen for the same reasons. The procedure:

1. Choose the site. Stay at least 2 inches (about 5 cm) from the navel, and avoid any scars, stretch marks, moles, or recent injection sites. The four quadrants of the abdomen — upper-left, upper-right, lower-left, lower-right — give you four rotation positions within the abdomen alone.

2. Clean the skin. Wipe the chosen site with an alcohol pad in a circular motion outward, covering an area roughly 2 inches across. Let the alcohol dry — injecting through wet alcohol stings.

3. Pinch a fold of skin between thumb and forefinger. The pinch lifts the subcutaneous fat away from the underlying muscle, creating a target zone that's clearly fat and not muscle.

4. Insert the needle at 90° in one smooth, decisive motion. Hesitation makes the injection hurt more, not less. For very lean individuals (BMI <22), a 45° angle reduces the risk of going through fat into muscle.

5. Release the pinch once the needle is in. Holding the pinch during injection isn't necessary and can affect the injection itself.

6. Push the plunger slowly and steadily over 5–10 seconds. A rapid push increases injection-site discomfort.

7. Wait 5 seconds before withdrawing the needle. This brief pause helps prevent the medication from leaking back out through the needle track.

8. Withdraw the needle at the same angle it was inserted. Pulling out at a different angle can cause unnecessary tissue trauma.

9. Apply gentle pressure with a clean cotton ball or gauze pad. Do not rub the injection site — rubbing can cause bruising and accelerate the medication's absorption rate beyond the intended profile.

10. Dispose of the syringe in a designated sharps container immediately. Never recap a used needle; needle-stick injuries account for the majority of injection-related accidents and recapping is the most common cause.

Site rotation — week to week

Don't inject the same exact spot two weeks in a row. The simplest rotation strategy is a 4-position rotation within the abdomen — upper-left, upper-right, lower-left, lower-right — moving clockwise each week. After four weeks you return to the first position, which by then has had a full month to recover. An alternative is to rotate between sites (abdomen → thigh → opposite thigh → abdomen), which spreads injection load across larger anatomical regions. Both approaches work; the goal is preventing localized lipohypertrophy (a thickening of the subcutaneous fat tissue at a frequently-injected spot, which can alter the absorption rate of subsequent injections at that site) and reducing the cumulative irritation from repeated needle entry at the same exact position.

How deep to inject retatrutide

Subcutaneous, not intramuscular. The needle goes into the fat layer (typically 5–15 mm deep depending on body composition) — not deeper. The standard 5/16" insulin needle is 8 mm in length, which lands cleanly in fat tissue for most adults at a 90° angle. A 1/2" (12.7 mm) needle is appropriate for individuals with thicker subcutaneous tissue. Going into muscle is not dangerous, but it is unnecessary and can increase absorption variability, since muscle has different blood flow than subcutaneous fat. The TRIUMPH trial protocols all specify subcutaneous administration; intramuscular injection of retatrutide is not part of any approved trial protocol and offers no efficacy advantage.

Should the injection hurt?

Most users describe the injection as a brief pinch — modern 27–31 gauge insulin needles are remarkably thin and most people find the alcohol pad more uncomfortable than the needle itself. Persistent or severe pain at the injection site, redness lasting more than 48 hours, swelling beyond a small bump, or warmth and tenderness spreading outward warrant evaluation. These can be signs of injection-site infection or, less commonly, an allergic-type reaction to the formulation. Bruising is common and not concerning unless extensive — small bruises happen when the needle nicks a capillary on entry or exit, and they resolve in 3–7 days without intervention.

What side effects should you expect, and which ones matter?

The most common retatrutide side effects are gastrointestinal — nausea (38–43% at higher doses), diarrhea (33–35%), vomiting (16–18%), and constipation — peaking during dose escalation and easing after 4–6 weeks at a stable dose. Dysesthesia (altered or enhanced skin sensation, including tingling, burning, or numbness) is a retatrutide-specific side effect, occurring in 8.8% of users at 9 mg and 20.9% at 12 mg in TRIUMPH-4 (versus 0.7% on placebo). Heart rate increases mildly during titration and typically returns toward baseline at maintenance dose. Most side effects are mild to moderate; severe side effects warrant clinical evaluation rather than self-management.

The TRIUMPH-4 discontinuation pattern is informative for users planning their own escalation. Discontinuation rates due to adverse events were 8.8% at 9 mg, 12.1% at 12 mg, and 4.0% on placebo — meaning roughly 1 in 12 users at 9 mg and 1 in 8 users at 12 mg stopped the drug because of side effects. Most discontinuations occurred during titration, not at maintenance. The implication for self-administering users: if side effects are intolerable at a given step, don't escalate further until they resolve. The data supports holding at a lower dose rather than pushing through with diminishing returns.

Why dysesthesia happens with retatrutide and not with semaglutide

The triple-agonist mechanism activates glucagon receptors in addition to GIP and GLP-1. Glucagon receptor activation in peripheral nerves is the leading hypothesis for the dysesthesia phenomenon, which appears in 20.9% of users at 12 mg versus 0.7% on placebo in TRIUMPH-4. The sensation is typically mild, intermittent, and most often described as transient tingling or altered sensation in the extremities — hands, feet, sometimes the scalp. It does not appear correlated with the magnitude or rate of weight loss and rarely leads to discontinuation in the trial data (most participants who experienced dysesthesia continued treatment). Neither semaglutide nor tirzepatide produces this signal because neither activates glucagon receptors. The honest framing: dysesthesia is a real consideration unique to retatrutide, but for most users it is a minor inconvenience rather than a treatment-limiting problem.

When to call a healthcare provider

Several patterns warrant medical evaluation rather than self-management:

• Severe abdominal pain, particularly radiating to the back — consider pancreatitis, a documented class effect for GLP-1 receptor agonists.

• Persistent vomiting beyond 24 hours or signs of dehydration (dizziness, very dark urine, no urination for 8+ hours).

• Severe gallbladder symptoms — right upper quadrant pain, particularly after eating fatty foods, accompanied by nausea.

• Persistent rapid heart rate at rest (above 100 bpm consistently) or palpitations.

• Severe injection-site reactions — spreading redness, warmth, fever, or pus indicate infection.

• New, severe, or progressive numbness or weakness in the limbs — distinguish from typical mild dysesthesia.

• Any symptom that simply concerns you. Retatrutide is investigational and not FDA-approved as of April 2026; medical guidance is essential when symptoms escalate, and self-administering an unapproved drug is a context where erring on the side of professional consultation is the right call.

How does retatrutide injection compare to tirzepatide and semaglutide?

Retatrutide, tirzepatide, and semaglutide are all once-weekly subcutaneous injections with similar reconstitution and injection technique. They differ in mechanism (single, dual, or triple receptor agonism), maximum dose (2.4 mg semaglutide / 15 mg tirzepatide / 12 mg retatrutide), and published efficacy (14.9% / 22.5% / 28.7% body-weight reduction in their respective Phase 3 trials). Retatrutide adds dysesthesia as a unique side effect; the GI profile is broadly comparable across all three.

Cross-trial comparisons are not head-to-head; trial populations and durations differ. For a deeper comparison covering mechanism, half-life, and side-effect profile across all three compounds, see Peptigrity's retatrutide vs tirzepatide vs semaglutide article. For the more granular tirzepatide-vs-semaglutide question that buyers often ask separately, see comparing semaglutide and tirzepatide. The compound profiles for tirzepatide and semaglutide cover the dosing schedules and indications for those compounds specifically.

The injection technique itself is essentially identical across the three. If you've injected semaglutide or tirzepatide before, retatrutide injection requires no new skill — the needle, the technique, the sites, and the rotation strategy are the same. The differences live in the dose schedule, the side-effect profile, and the regulatory status, not in the mechanics of getting the drug under your skin.

How do you know the retatrutide you're injecting is real?

Research-grade retatrutide is sold without FDA oversight, which makes independent third-party testing the buyer's primary quality safeguard. Verify three things before injecting any vial: HPLC purity ≥98% for the named compound, mass-spectrometry identity confirmation matching retatrutide's molecular weight (~4,731 Da), and a Certificate of Analysis from a named independent lab (Janoshik Analytical, Chromate Analytics, MZ Biolabs, etc.) with a portal-verifiable Task or Job number. Counterfeit GLP-1-class compounds are widespread; identity verification matters more than purity verification for these compounds, because a vial labeled "retatrutide" may contain semaglutide or tirzepatide instead.

The identity-substitution risk is specific and well-documented. Janoshik Analytical operates a GLP-1 blind test specifically because semaglutide-tirzepatide-retatrutide substitution is common enough in the research-peptide market to warrant a dedicated assay — the test identifies which of the three compounds is actually in the vial without the buyer pre-declaring which is suspected. For a vial labeled "retatrutide" sourced from a vendor whose track record you don't yet trust, the GLP-1 blind test is the analytical move that answers the identity question directly. Beyond identity, endotoxin testing for peptides covers the LPS-contamination question that matters for chronic-use injectables like retatrutide where the same vial is drawn from weekly across 4–10 weeks.

For the full pre-purchase checklist tailored to retatrutide specifically — the seven verification steps that apply to this compound's market quirks — see Peptigrity's where to buy retatrutide guide. Peptigrity's lab tests database tracks HPLC and identity test results for retatrutide samples across the shops we review, and the testing labs directory lists the independent labs where you can submit your own vial for verification.

Is retatrutide legal to inject?

Retatrutide is not FDA-approved as of April 2026. Eli Lilly is conducting eight Phase 3 trials in the TRIUMPH program, with seven additional readouts expected in 2026. Legal status varies by jurisdiction: research-use-only sales are common in the US, the UK, and the EU under research-chemical framing, but importing or self-administering an unapproved drug carries regulatory risk that varies meaningfully by country. Retatrutide is not currently on the WADA prohibited list as a named substance (it would fall under S0 anabolic agents categorization if banned). Verify your specific jurisdiction's status before purchasing, and verify it again before chronic use.

The compounding pharmacy pathway that is currently available for semaglutide and tirzepatide under FDA's 503A and 503B frameworks is not currently established for retatrutide because the drug is not yet FDA-approved. This means there is no "compounded retatrutide" prescription option from a US compounding pharmacy as of April 2026 — the only realistic access is either clinical trial enrollment or research-peptide vendors. For users considering the latter, the where to buy retatrutide guide covers vendor selection in detail. For the prescription-status question specifically, see do you need a prescription for retatrutide; for country-by-country regulatory framework see peptide legality by country; for the broader US regulatory timeline see the FDA peptide regulation timeline.

Writer note: regulatory status changes frequently; verify FDA approval status, WADA listing, and country-specific framework against the linked regulators at time of writing and update the "as of April 2026" markers in this section if current information has shifted.

Frequently Asked Questions

How long until I see results from retatrutide?

TRIUMPH-4 data show progressive weight loss over the full 68-week trial duration. Most users see 5–7% body-weight loss by week 12 during titration (when they're still at 2–6 mg), 15–20% by week 24 as they reach maintenance dose, and the full ~28% effect by week 68 at 12 mg. Early weight loss within the first 4 weeks at the 2 mg starting dose is common but modest; the steeper losses come during the 9–12 mg maintenance phase. Plateaus are normal; the trial data shows weight loss continued slowly even past week 48 in many participants.

Can I inject retatrutide in my thigh instead of my stomach?

Yes. The thigh — front-outer aspect, mid-thigh — is one of the three approved subcutaneous injection sites alongside the abdomen and upper arm. Many users rotate between stomach and thigh week to week to reduce localized irritation. The thigh is easiest to inject when seated and may be the preferred site for users with significant abdominal scarring or extensive prior injection history at the abdominal sites.

How many times a week to inject retatrutide?

Once. Retatrutide's ~6-day half-life is engineered specifically for once-weekly dosing. Twice-weekly or daily dosing is not supported by any trial data and would not produce additional benefit — by the time the next weekly dose is due, ~50% of the previous week's dose remains in circulation, and adding a second weekly injection would simply create higher peak concentrations without changing the underlying weight-loss trajectory.

What time of day should I inject retatrutide?

Any time of day; consistency matters more than the specific hour. Choose a time you'll reliably remember weekly. The TRIUMPH trials did not specify a time of day — participants chose what worked for them. Many users inject in the evening so that any gastrointestinal side effects occur during sleep rather than during the workday; others prefer morning injection to align with weekly routines. Both approaches work.

Can I inject retatrutide while taking other GLP-1 receptor agonists?

No. Combining retatrutide with semaglutide, tirzepatide, liraglutide, or other GLP-1-class compounds is not supported by any trial data and is not clinically advised. Switching from one GLP-1 to another typically requires a washout period to allow the previous compound to clear; consult a healthcare provider before switching. Stacking GLP-1s amplifies gastrointestinal side effects without additional efficacy benefit and is one of the higher-risk practices documented in research-peptide community forums.

How long does retatrutide take to wear off after the last dose?

With a ~6-day half-life, plasma concentrations decline progressively over 4–6 weeks after the last injection. Appetite and metabolic effects gradually return as the drug clears. This long tail is also why dose escalation must be patient — the previous week's dose has not fully cleared by the time the next dose is given, which is the basis of the 4-week step-up interval. For users planning to stop retatrutide, the gradual taper is essentially built into the pharmacokinetics; abrupt discontinuation produces a slower, smoother return to baseline than equivalent discontinuation from shorter-acting GLP-1s.

Do I need a sharps container?

Yes. Used insulin syringes go into a designated sharps container — never into regular trash or recycling. Most pharmacies sell sharps containers for $5–$15, and many municipalities accept them at hazardous-waste drop-off sites. Some users improvise with rigid plastic detergent bottles in low-resource settings, though purpose-built containers are preferable for puncture resistance. Sharps disposal is not just regulatory etiquette — it prevents needle-stick injuries to sanitation workers and other people downstream of your trash.

Can I freeze retatrutide?

No. Reconstituted retatrutide should be refrigerated at 2–8°C but not frozen. Freezing can destabilize the peptide structure and potentially fragment the molecule. Lyophilized (un-reconstituted) vials can be stored at refrigerated temperature; some lyophilized peptides tolerate frozen storage of the un-reconstituted vial, but verify the vendor's stated storage instructions for your specific batch. Discard reconstituted retatrutide after 28 days regardless of how the vial looks — the BAC water's preservative system loses effectiveness on that timeline and continued use risks microbial contamination.

This article is for educational and informational purposes only and does not constitute medical advice. Retatrutide (LY3437943) is an investigational drug not approved by the FDA, EMA, or other major regulators as of April 2026; Eli Lilly's TRIUMPH Phase 3 program is ongoing. Peptigrity is an independent peptide review platform — we do not sell peptides, take no affiliate commissions from any vendor, and have no commercial relationship with Eli Lilly. Always consult a qualified healthcare provider before injecting any compound, including investigational peptides. Most peptides referenced on this site are not FDA-approved for human use; regulatory status varies by country and changes frequently.